RLY-4008

· Elevar Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RLY-4008, covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors [Phase 1, Phase 2]

See pricing